Post-treatment Effects of Erythropoietin and Nordihydroguaiaretic Acid on Recovery from Cisplatin-induced Acute Renal Failure in the Rat

다국어 초록 (Multilingual Abstract)

5-Lipoxygenase inhibitor and human recombinant erythropoietin might accelerate

renal recovery in cisplatin-induced acute renal failure rats. Male Sprague-Dawley rats

were randomized into four groups: 1) normal controls; 2) Cisplatin group-cisplatin

induced acute renal failure (ARF) plus vehicle treatment; 3) Cisplatin+nordihydroguaiaretic

acid (NDGA) group-cisplatin induced ARF plus 5-lipoxygenase inhibitor treatment;

4) Cisplatin+erythropoietin (EPO) group-cisplatin induced ARF plus erythropoietin

treatment. On day 10 (after 7 daily injections of NDGA or EPO), urea nitrogen

and serum Cr concentrations were significantly lower in the Cisplatin+NDGA

and Cisplatin+EPO groups than in the Cisplatin group, and 24 hr urine Cr clearances

were significantly higher in the Cisplatin+EPO group than in the Cisplatin group. Semiquantitative

assessments of histological lesions did not produce any significant differences

between the three treatment groups. Numbers of PCNA(+) cells were significantly

higher in Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups than in

normal controls. Those PCNA(+) cells were significantly increased in Cisplatin+NDGA

group. These results suggest that EPO and also NDGA accelerate renal function

recovery by stimulating tubular epithelial cell regeneration.

참고문헌 (Reference)

1 Foster S, "Tyler’s Honest Herbal: a sensible guide to the use of herbs and related remedies" Haworth Herbal Press 109-111, 1999

2 Westenfelder C, "Tubular and mesangial cells of human, rat and mouse kidney express authentic erythropoietin receptor mRNA" S22-, 1997

3 Brent J, "Three new herbal hepatotoxic syndromes" 37 : 715-719, 1999

4 Kollman-Bauerly KA, "The role of eicosanoids in the process of adaptation following massive bowel resection in the rat" 25 : 275-281, 2001

5 Marchenko HI, "The correction of disorders in arachidonic acid metabolism in coronary spasm of an immune origin" 40 : 81-87, 1994

6 Jacobson LO, "Role of the kidney in erythropoiesis" 179 : 633-634, 1957

7 Blachley JD, "Renal and electrolyte disturbances associated with cisplatin" 95 : 628-632, 1981

8 Carlini RG, "Recombinant human erythropoietin stimulates angiogenesis in vitro" 47 : 740-745, 1995

9 Kitagawa S, "Recombinant human erythropoietin at high doses stimulates thrombopoiesis: treatment for protracted severe myelosuppression complicating interferon-alpha and busulfan therapy for chronic myelogenous leukemia" 55 : 285-286, 1995

10 Nemoto T, "Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure" 59 : 246-251, 2001

11 Ezberci F, "Protective effect of a lipoxygenase inhibitor, nordihydroguaiaretic acid, on the ileal motor disturbances induced by Serratia marcescens endotoxin in rats" 31 : 497-501, 2001

12 Anjaneyulu M, "Nordihydroguairetic acid, a lignin, prevents oxidative stress and the development of diabetic nephropathy in rats" 72 : 42-50, 2004

13 Brady HR, "Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules" 258 : F1181-F1187, 1990

14 Lara F, "Medicinal plants from Mexico: composition, uses and biological activity" UNAM 9-61, 1996

15 Brinker F, "Larrea tridentata (DC) Coville (chaparral or creosote bush)" 3 : 10-31, 1993

16 Cvitkovic E, "Improvement of Cis-dichlorodiamineplatinum (NCS 119875): therapeutic index in an animal model" 39 : 1357-1361, 1977

17 Fraser JK, "Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes" 17 : 10-16, 1989

18 Winkelman M, "Ethnobotanical treatments of diabetes in Baja California Norte" 11 : 255-268, 1989

19 Anagnostou A, "Erythropoietin receptor mRNA expression in human endothelial cells" 91 : 3974-3978, 1994

20 Anagnostou A, "Erythropoietin has a mitogenic effect and a positive chemotactic effect on endothelial cells" 87 : 5978-5982, 1990

21 Bagnis C, "Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat" 16 : 932-938, 2001

22 Nagai T, "Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells" 10 : 1814-1819, 1995

23 Loehrer PJ, "Drugs five years later. Cisplatin" 100 : 704-713, 1984

24 Leibbrandt ME, "Critical subcellular targets of cisplatin and related platinum analogs in renal proximal tubule cells" 48 : 761-770, 1995

25 Mabry TJ, "Creosote bush. Biology and chemistry of Larrea in new world deserts" Hutchinson & Ross 1979

26 Heidemann TH, "Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide" 329 : 201-205, 1985

27 Argueta A, "Atlas of the Traditional Mexican Medicinal Plants (vol II)" National Indigenous Institute 669-670, 1994

28 Sugiyama S, "Adverse effects of anti-cancer drug, cisplatin on rat kidney mitochondria: disturbances in glutathione peroxidase activity" 159 : 1121-1127, 1989

29 Thadhani R, "Acute renal failure" 334 : 1448-1460, 1996

30 Kharbanda S, "Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents" 376 : 785-788, 1995

31 Daley-Yates PT, "A study of the protective effect of chloride salts on cisplatin nephrotoxicity" 34 : 2363-2369, 1985

32 Dillman RO, "A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer" 323 : 940-945, 1990